MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.nicl.2026.103963

Медицинская библиотека · NeuroImage. Clinical · 2026

Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.

Eckenweber Sebastian, Völter Friederike, Franzmeier Nicolai, Palleis Carla, Wagemann Olivia, Weidinger Endy, Katzdobler Sabrina, Wlasich Elisabeth, Sandkühler Katja, Böning Guido, Gnörich Johannes, Scheifele Maximilian, Eckenweber Florian, Janowitz Daniel, Kurz Carolin, Perneczky Robert, Bürger Katharina, Danek Adrian, Höglinger Günter, Levin Johannes, Brendel Matthias, Schönecker Sonja

СтатьяПеревод в очереди

Аннотация

PURPOSE: Recent studies demonstrated strong agreement between early-phase β-amyloid-PET perfusion imaging and glucose hypometabolism assessed by [18F]FDG-PET, indicating the potential of early-phase β-amyloid-PET as a surrogate biomarker of neuronal injury. We therefore aimed to investigate the additive value of early-phase β-amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia syndromes in clinical routine.

MATERIALS AND

METHODS

[18F]florbetaben- and [18F]flutemetamol-PET scans (n = 379) performed between July 2013 and July 2021 were analyzed for their amyloid status and the presence of a neurodegenerative hypoperfusion pattern using visual assessment and z-score maps. In patients visually rated as amyloid-negative/neurodegeneration-positive (A-N+), the most likely diagnosis based on perfusion patterns was compared to the final clinical diagnosis, i.e. frontotemporal dementia or psychiatric disorders, suspected 4R-tauopathy, and suspected non-Alzheimer pathophysiology. Logistic regression models based on a data-driven selection of cerebral regions of hypoperfusion by principal component analysis were used to predict neurodegenerative disease and clinical diagnoses. Diagnostic accuracy was compared between visual assessment and the regression models.

RESULTS

Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. Visual assessment assigned 75.3% (67/89) of A-N+ patients to the correct diagnostic category. In contrast, the regression model classified 69.7% (62/89) of patients.

CONCLUSIONS

The current study demonstrates an additive value of early-phase β-amyloid-PET for the differential diagnosis of dementia syndromes. While visual assessment of early-phase β-amyloid-PET already provides substantial diagnostic accuracy, a data-driven analysis approach could aid in cases of uncertainty.

Для цитирования: Eckenweber Sebastian, Völter Friederike, Franzmeier Nicolai, Palleis Carla, Wagemann Olivia, Weidinger Endy, Katzdobler Sabrina, Wlasich Elisabeth, Sandkühler Katja, Böning Guido, Gnörich Johannes, Scheifele Maximilian, Eckenweber Florian, Janowitz Daniel, Kurz Carolin, Perneczky Robert, Bürger Katharina, Danek Adrian, Höglinger Günter, Levin Johannes, Brendel Matthias, Schönecker Sonja. Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.. NeuroImage. Clinical. 2026. DOI: 10.1016/j.nicl.2026.103963.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.